Skip to content

Study · Randomized controlled trial · n = 23 · 2008

2 results

Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.

Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis G, Kita M, Avramidis A

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme15 Feb 2008Cited by 18 (Europe PMC)

PMID18275008 (opens in a new tab)DOI10.1055/s-2008-1046787 (opens in a new tab)PepBankPUB-18275008
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, P1NP increased throughout teriparatide treatment compared with baseline.

    In plain wordsTeriparatide increased the bone marker P1NP compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseP1NP
    Study

    n = 23

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg once daily · six monthsAs given in this study (human).

    Source sentences

    Summary
    P1NP and CTx levels remained unchanged in group 1, decreased in group 2 (p<0.001), and increased in group 3 women (p<0.001) throughout the treatment.
    1 context sentence
    Summary · context
    Women with osteoporosis were randomly assigned to either risedronate 35 mg once weekly (group 2, n=21) or teriparatide 20 microg once daily (group 3, n=23) for six months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with osteoporosis, CTx increased throughout teriparatide treatment compared with baseline.

    In plain wordsTeriparatide increased the bone marker CTx compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCTx
    Study

    n = 23

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg once daily · six monthsAs given in this study (human).

    Source sentences

    Summary
    P1NP and CTx levels remained unchanged in group 1, decreased in group 2 (p<0.001), and increased in group 3 women (p<0.001) throughout the treatment.
    1 context sentence
    Summary · context
    Women with osteoporosis were randomly assigned to either risedronate 35 mg once weekly (group 2, n=21) or teriparatide 20 microg once daily (group 3, n=23) for six months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.